164 related articles for article (PubMed ID: 34738648)
21. The gut microbiome and irritable bowel syndrome: State of art review.
Salem AE; Singh R; Ayoub YK; Khairy AM; Mullin GE
Arab J Gastroenterol; 2018 Sep; 19(3):136-141. PubMed ID: 29935865
[TBL] [Abstract][Full Text] [Related]
22. Gut microbiota as potential orchestrators of irritable bowel syndrome.
Bennet SM; Ohman L; Simren M
Gut Liver; 2015 May; 9(3):318-31. PubMed ID: 25918261
[TBL] [Abstract][Full Text] [Related]
23. Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.
Yan R; Murphy M; Genoni A; Marlow E; Dunican IC; Lo J; Andrew L; Devine A; Christophersen CT
BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32816830
[TBL] [Abstract][Full Text] [Related]
24. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome.
Pigrau M; Rodiño-Janeiro BK; Casado-Bedmar M; Lobo B; Vicario M; Santos J; Alonso-Cotoner C
Neurogastroenterol Motil; 2016 Apr; 28(4):463-86. PubMed ID: 26556786
[TBL] [Abstract][Full Text] [Related]
25. Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome.
Singh P; Lembo A
Gastroenterol Clin North Am; 2021 Sep; 50(3):523-545. PubMed ID: 34304786
[TBL] [Abstract][Full Text] [Related]
26. The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders.
Thumann TA; Pferschy-Wenzig EM; Moissl-Eichinger C; Bauer R
J Ethnopharmacol; 2019 Dec; 245():112153. PubMed ID: 31408679
[TBL] [Abstract][Full Text] [Related]
27. Diet and the Microbiome.
Murtaza N; Ó Cuív P; Morrison M
Gastroenterol Clin North Am; 2017 Mar; 46(1):49-60. PubMed ID: 28164852
[TBL] [Abstract][Full Text] [Related]
28. Irritable bowel syndrome: a gut microbiota-related disorder?
Bhattarai Y; Muniz Pedrogo DA; Kashyap PC
Am J Physiol Gastrointest Liver Physiol; 2017 Jan; 312(1):G52-G62. PubMed ID: 27881403
[TBL] [Abstract][Full Text] [Related]
29. [Irritable bowel syndrome: Role of gut microbiota].
Lajoie F; Rousseau G; Blanquet-Diot S; Etienne-Mesmin L
Med Sci (Paris); 2021; 37(6-7):593-600. PubMed ID: 34180818
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms Underlying Food-Triggered Symptoms in Disorders of Gut-Brain Interactions.
Van den Houte K; Bercik P; Simren M; Tack J; Vanner S
Am J Gastroenterol; 2022 Jun; 117(6):937-946. PubMed ID: 35506862
[TBL] [Abstract][Full Text] [Related]
31. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study.
Kurokawa S; Kishimoto T; Mizuno S; Masaoka T; Naganuma M; Liang KC; Kitazawa M; Nakashima M; Shindo C; Suda W; Hattori M; Kanai T; Mimura M
J Affect Disord; 2018 Aug; 235():506-512. PubMed ID: 29684865
[TBL] [Abstract][Full Text] [Related]
32. [Irritable Bowel Syndrome, Emotion Regulation, and Gut Microbiota].
Fukudo S
Brain Nerve; 2016 Jun; 68(6):607-15. PubMed ID: 27279158
[TBL] [Abstract][Full Text] [Related]
33. The Gut-Brain Axis.
Mayer EA; Nance K; Chen S
Annu Rev Med; 2022 Jan; 73():439-453. PubMed ID: 34669431
[TBL] [Abstract][Full Text] [Related]
34. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.
O'Malley D
Exp Physiol; 2019 Jan; 104(1):3-10. PubMed ID: 30444291
[TBL] [Abstract][Full Text] [Related]
35. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge.
Labanski A; Langhorst J; Engler H; Elsenbruch S
Psychoneuroendocrinology; 2020 Jan; 111():104501. PubMed ID: 31715444
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
37. Targeted pharmacotherapy of irritable bowel syndrome.
Arokiadoss A; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):214-221. PubMed ID: 33481423
[TBL] [Abstract][Full Text] [Related]
38. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome.
Chen M; Ruan G; Chen L; Ying S; Li G; Xu F; Xiao Z; Tian Y; Lv L; Ping Y; Cheng Y; Wei Y
Front Endocrinol (Lausanne); 2022; 13():817100. PubMed ID: 35250873
[TBL] [Abstract][Full Text] [Related]
39. Targeting the gut microbiota for the treatment of irritable bowel syndrome.
Herndon CC; Wang YP; Lu CL
Kaohsiung J Med Sci; 2020 Mar; 36(3):160-170. PubMed ID: 31782606
[TBL] [Abstract][Full Text] [Related]
40. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
